NasdaqGS:RVMDBiotechs
Revolution Medicines Recasts RAS Story With Phase 3 Win And New Firepower
Revolution Medicines reported groundbreaking overall survival results from its pivotal Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer.
The company entered a major clinical collaboration with Summit Therapeutics to study RAS(ON) inhibitor combinations across RAS mutant cancers.
Revolution Medicines also announced plans to acquire EQRx, Inc., aiming to significantly increase its capital resources.
These updates come as Revolution Medicines, ticker NasdaqGS:RVMD,...